Cargando…
Iron Treatment May Be Difficult in Inflammatory Diseases: Inflammatory Bowel Disease as a Paradigm
Iron plays a key role in many physiological processes; cells need a very exact quantity of iron. In patients with inflammatory bowel disease, anaemia is a unique example of multifactorial origins, frequently being the result of a combination of iron deficiency and anaemia of chronic disease. The mai...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316243/ https://www.ncbi.nlm.nih.gov/pubmed/30544934 http://dx.doi.org/10.3390/nu10121959 |
_version_ | 1783384483383214080 |
---|---|
author | Gargallo-Puyuelo, Carla J. Alfambra, Erika García-Erce, Jose Antonio Gomollon, Fernando |
author_facet | Gargallo-Puyuelo, Carla J. Alfambra, Erika García-Erce, Jose Antonio Gomollon, Fernando |
author_sort | Gargallo-Puyuelo, Carla J. |
collection | PubMed |
description | Iron plays a key role in many physiological processes; cells need a very exact quantity of iron. In patients with inflammatory bowel disease, anaemia is a unique example of multifactorial origins, frequently being the result of a combination of iron deficiency and anaemia of chronic disease. The main cause of iron deficiency is the activity of the disease. Therefore, the first aim should be to reach complete clinical remission. The iron supplementation route should be determined according to symptoms, severity of anaemia and taking into account comorbidities and individual risks. Oral iron can only be used in patients with mild anaemia, whose disease is inactive and who have not been previously intolerant to oral iron. Intravenous iron should be the first line treatment in patients with moderate-severe anaemia, in patients with active disease, in patients with poor tolerance to oral iron and when erythropoietin agents or a fast response is needed. Erythropoietin is used in a few patients with anaemia to overcome functional iron deficiency, and blood transfusion is being restricted to refractory cases or acute life-threatening situations. |
format | Online Article Text |
id | pubmed-6316243 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-63162432019-01-08 Iron Treatment May Be Difficult in Inflammatory Diseases: Inflammatory Bowel Disease as a Paradigm Gargallo-Puyuelo, Carla J. Alfambra, Erika García-Erce, Jose Antonio Gomollon, Fernando Nutrients Review Iron plays a key role in many physiological processes; cells need a very exact quantity of iron. In patients with inflammatory bowel disease, anaemia is a unique example of multifactorial origins, frequently being the result of a combination of iron deficiency and anaemia of chronic disease. The main cause of iron deficiency is the activity of the disease. Therefore, the first aim should be to reach complete clinical remission. The iron supplementation route should be determined according to symptoms, severity of anaemia and taking into account comorbidities and individual risks. Oral iron can only be used in patients with mild anaemia, whose disease is inactive and who have not been previously intolerant to oral iron. Intravenous iron should be the first line treatment in patients with moderate-severe anaemia, in patients with active disease, in patients with poor tolerance to oral iron and when erythropoietin agents or a fast response is needed. Erythropoietin is used in a few patients with anaemia to overcome functional iron deficiency, and blood transfusion is being restricted to refractory cases or acute life-threatening situations. MDPI 2018-12-11 /pmc/articles/PMC6316243/ /pubmed/30544934 http://dx.doi.org/10.3390/nu10121959 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Gargallo-Puyuelo, Carla J. Alfambra, Erika García-Erce, Jose Antonio Gomollon, Fernando Iron Treatment May Be Difficult in Inflammatory Diseases: Inflammatory Bowel Disease as a Paradigm |
title | Iron Treatment May Be Difficult in Inflammatory Diseases: Inflammatory Bowel Disease as a Paradigm |
title_full | Iron Treatment May Be Difficult in Inflammatory Diseases: Inflammatory Bowel Disease as a Paradigm |
title_fullStr | Iron Treatment May Be Difficult in Inflammatory Diseases: Inflammatory Bowel Disease as a Paradigm |
title_full_unstemmed | Iron Treatment May Be Difficult in Inflammatory Diseases: Inflammatory Bowel Disease as a Paradigm |
title_short | Iron Treatment May Be Difficult in Inflammatory Diseases: Inflammatory Bowel Disease as a Paradigm |
title_sort | iron treatment may be difficult in inflammatory diseases: inflammatory bowel disease as a paradigm |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316243/ https://www.ncbi.nlm.nih.gov/pubmed/30544934 http://dx.doi.org/10.3390/nu10121959 |
work_keys_str_mv | AT gargallopuyuelocarlaj irontreatmentmaybedifficultininflammatorydiseasesinflammatoryboweldiseaseasaparadigm AT alfambraerika irontreatmentmaybedifficultininflammatorydiseasesinflammatoryboweldiseaseasaparadigm AT garciaercejoseantonio irontreatmentmaybedifficultininflammatorydiseasesinflammatoryboweldiseaseasaparadigm AT gomollonfernando irontreatmentmaybedifficultininflammatorydiseasesinflammatoryboweldiseaseasaparadigm |